Have a feature idea you'd love to see implemented?
Let us know!
RCUS Arcus Biosciences Inc
Price (delayed)
$13.82
Market cap
$1.26B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.15
Enterprise value
$1.11B
Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs.
Highlights
RCUS's revenue has soared by 119% YoY and by 6% QoQ
The gross profit has soared by 119% YoY and by 6% from the previous quarter
RCUS's equity is down by 11% since the previous quarter but it is up by 9% year-on-year
The net income is down by 8% since the previous quarter but it is up by 8% year-on-year
Key stats
What are the main financial stats of RCUS
Market
Valuations
Earnings
Shares outstanding
91.51M
Market cap
$1.26B
Enterprise value
$1.11B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.24
Price to sales (P/S)
4.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.22
Revenue
$263M
Gross profit
$263M
Net income
-$270M
EBIT
-$268M
EBITDA
-$251M
Free cash flow
-$169M
Per share
Balance sheet
Liquidity
EPS
-$3.15
EPS diluted
-$3.15
Free cash flow per share
-$1.85
Book value per share
$6.18
Revenue per share
$2.88
TBVPS
$13.7
Total assets
$1.25B
Total liabilities
$687M
Debt
$47M
Equity
$565M
Working capital
$912M
Debt to equity
0.08
Current ratio
5.24
Quick ratio
5.14
Net debt/EBITDA
0.61
Margins
Efficiency
Dividend
EBITDA margin
-95.4%
Gross margin
100%
Net margin
-102.7%
Operating margin
-120.9%
Return on assets
-22.4%
Return on equity
-45.6%
Return on invested capital
-31.5%
Return on capital employed
-25.8%
Return on sales
-101.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RCUS stock price
How has the Arcus Biosciences stock price performed over time
Intraday
-0.79%
1 week
-9.32%
1 month
-14.05%
1 year
-21.07%
YTD
-7.19%
QTD
-7.19%
Financial performance
How have Arcus Biosciences's revenue and profit performed over time
Revenue
$263M
Gross profit
$263M
Operating income
-$318M
Net income
-$270M
Gross margin
100%
Net margin
-102.7%
RCUS's revenue has soared by 119% YoY and by 6% QoQ
The gross profit has soared by 119% YoY and by 6% from the previous quarter
Arcus Biosciences's net margin has soared by 58% YoY
The operating margin has surged by 55% year-on-year
Growth
What is Arcus Biosciences's growth rate over time
Valuation
What is Arcus Biosciences stock price valuation
P/E
N/A
P/B
2.24
P/S
4.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.22
RCUS's EPS is up by 21% year-on-year
RCUS's price to book (P/B) is 23% lower than its 5-year quarterly average of 2.9 and 10% lower than its last 4 quarters average of 2.5
RCUS's equity is down by 11% since the previous quarter but it is up by 9% year-on-year
RCUS's revenue has soared by 119% YoY and by 6% QoQ
RCUS's P/S is 75% below its 5-year quarterly average of 18.9 and 36% below its last 4 quarters average of 7.5
Efficiency
How efficient is Arcus Biosciences business performance
RCUS's return on sales has surged by 57% year-on-year but it is down by 2.7% since the previous quarter
The return on equity has increased by 9% year-on-year but it has declined by 6% since the previous quarter
Arcus Biosciences's return on assets has decreased by 7% QoQ but it has increased by 4.3% YoY
RCUS's ROIC is up by 7% YoY but it is down by 7% from the previous quarter
Dividends
What is RCUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RCUS.
Financial health
How did Arcus Biosciences financials performed over time
The total assets is 82% greater than the total liabilities
The total liabilities has increased by 25% since the previous quarter and by 2.4% year-on-year
RCUS's quick ratio is up by 21% year-on-year and by 2.6% since the previous quarter
Arcus Biosciences's debt is 92% less than its equity
RCUS's equity is down by 11% since the previous quarter but it is up by 9% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.